PharmaCyte Biotech, Inc.(PMCB)Earnings, Financials & Key Ratios
PMCB•NASDAQ
$0.77
0.2× P/E·Price updated Jun 27, 2026
AboutPharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Show more
- Revenue$0
- EBITDA$31M
- Net Income$31M+9085.0%
- EPS (Diluted)3.19+277.2%
- ROE67.08%+11175.3%
PMCB Price & Volume
PharmaCyte Biotech, Inc. (PMCB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Stagnation Masks Capital Erosion Risks
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:FDA clinical hold resolution
"PharmaCyte Biotech remains a pre-revenue entity struggling with a prolonged FDA clinical hold that prevents the commercialization of its Cell-in-a-Box technology. The company's reliance on non-cash accounting adjustments to report net income, such as the $11.7M profit in 2025Q4, masks a fundamental inability to generate operational cash flow. Investors should remain cautious as the firm continues to deplete its cash reserves, which have declined from $73.4M in 2024Q2 to $20.2M in 2026Q3, while maintaining high administrative overhead."
Verdict Logic
the company's rapid cash depletion, with reserves falling to $20.2M in 2026Q3, combined with a lack of clinical progress, suggests significant long-term solvency risks for shareholders.
PMCB Growth Metrics
PharmaCyte Biotech, Inc. (PMCB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-127.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-235.06%
Return on Capital
10 Years-50.73%
5 Years-19.43%
3 Years-8.91%
Last Year-8.36%
Peers Comparison
Key metrics vs top competitors for PharmaCyte Biotech, Inc. (PMCB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $8.26M | 0.24 | — | — | 67.08% | 20.02% | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $0.41 | $4.23M | -0.19 | — | — | -246.04% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $46.23 | $2.36B | 144.47 | 16.45% | 7.35% | 6.41% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — |
Compare PMCB vs Peers
PharmaCyte Biotech, Inc. (PMCB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PMCB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMCB Frequently Asked Questions
PharmaCyte Biotech, Inc. (PMCB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PMCB profitable?
PharmaCyte Biotech, Inc. (PMCB) reported a net loss of $5.6M for fiscal year 2025.
Dividend & Returns
Does PMCB pay dividends?
Yes, PharmaCyte Biotech, Inc. (PMCB) pays a dividend with a yield of 20.02%. This makes it attractive for income-focused investors.
What is PMCB's return on equity?
PharmaCyte Biotech, Inc. (PMCB) has a return on equity (ROE) of 67.1%. This is excellent, indicating efficient use of shareholder capital.
What is PharmaCyte Biotech, Inc.'s free cash flow?
PharmaCyte Biotech, Inc. (PMCB) had negative free cash flow of $4.8M in fiscal year 2025, likely due to heavy capital investments.